# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Vernon Bernardino maintains Artelo Biosciences (NASDAQ:ARTL) with a Buy and maintains $5 pri...
Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of ...
Fiscal 2023 Year-End Financial ResultsCash and Investments: Cash and investments totalled $10.4 million as of December 31, 2023...
https://register.epo.org/application?number=EP18887462
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways...
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways...